Clinical Study

Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients: Classification according to Hormone Production and Cytokeratin Distribution

Ryosuke Mori,1 Naoko Inoshita,2 Junko Takahashi-Fujigasaki,3 Tatsuhiro Joki,1 Hiroshi Nishioka,4 Toshiaki Abe,1 Takeshi Fujii,2 and Shozo Yamada 4,5

1 Department of Neurosurgery, The Jikei University School of Medicine, 3-25-8 Nishishinbashishi, Minato-ku, Tokyo 105-8461, Japan
2 Department of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
3 Division of Neuropathology, The Jikei University School of Medicine, 3-25-8 Nishishinbashishi, Minato-ku, Tokyo 105-8461, Japan
4 Division of Hypothalamic and Pituitary Surgery, Toranomon Hospital, Tokyo 105-8470, Japan
5 Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan

Correspondence should be addressed to Ryosuke Mori; ryotam@jikei.ac.jp

Received 26 October 2012; Accepted 20 November 2012

Academic Editors: R. V. Garcia-Mayor, S. La Rosa, and J. A. Rillema

Copyright © 2013 Ryosuke Mori et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study was to clarify the relationship between the histological features of GH-producing adenomas surgically resected at the Toranomon Hospital and the clinical features of the patients. Histological examinations, including immunohistochemistry for anterior pituitary hormones and cytokeratin (CK), were performed on 242 consecutively excised GH-producing pituitary adenomas. Immunohistochemistry showed 45% of the adenomas to be monohormonal and 55% to be plurihormonal, producing GH-PRL (77%), GH-TSH (13%), and GH-PRL-TSH (10%). One-fourth of the monohormonal GH adenomas had a dot-like pattern of CK immunoreactivity in the majority of the tumor cells (>80%); they were significantly more common in female or younger patients and usually tended to be larger and more invasive than monohormonal GH adenomas with perinuclear CK. Interestingly, CK-immunonegative adenomas were found in only 5% of the patients; they also showed a tendency to be larger, suggesting that they are a distinct type of GH adenoma with clinically aggressive features. Serum hormone levels correlated well with tumor size only in GH-producing adenomas with a perinuclear pattern of CK immunoreactivity. Each histological subtype of adenoma, classified according to the pattern of CK immunoreactivity, was associated with distinct clinical characteristics. This information is useful for understanding the pathophysiology of acromegaly-causing GH-producing adenomas.

1. Introduction

Acromegaly is a syndrome caused by overproduction of growth hormone (GH), which is secreted, in majority of the patients, from GH-producing pituitary adenomas [1]. It is well known that GH-producing pituitary adenomas often coexpress prolactin (PRL) and, less frequently, thyroid stimulating hormone (TSH) [1]. Production of anterior pituitary hormones in nonneoplastic as well as neoplastic cells is controlled by several transcription factors and cofactors [2]. Accumulating evidence supports the hypothesis that normal and adenoma cells expressing GH, PRL, and TSH are regulated by the pituitary-specific transcription factor-1 (Pit-1) and, therefore, belong to the Pit-1 cell lineage [2–7].

Histologically, monohormonal GH-producing adenomas are classified in two subtypes, densely granulated (DG) and sparsely granulated (SG), based on the density of secretory granules in the cytoplasm of the adenoma cells [1, 8, 9]. These two types of tumors appear to have different clinical, endocrinological, and neuroimaging features [9–13]. It is therefore of importance to identify their histological subtypes. DG- and SG-type cells have different cytoskeletal
features, with or without the formation of fibrous bodies, the hallmark of SG type cells, which are globular aggregations of intermediate filaments as seen on electron micrographs [13–17]. This spherical aggregate can also be detected as dot-like structure immunostained with an antibody against cytokeratin (CK). In DG type cells, CK immunostaining is perinuclear [12, 13]. Adenomas are diagnosed according to the ratio of DG- and SG-type features, which are conventionally distinguished by the pattern of distribution of CK [12, 13]. The distribution of CK also varies in plurihormonal GH adenomas. These adenomas are histologically subcategorized by electron microscopic analysis. However, the subtypes are difficult to predict on the basis of the CK pattern alone [8].

In this study, we examined pathological features of pituitary adenomas surgically resected from 242 patients with clinical symptoms of acromegaly. The adenomas were subcategorized according to hormone secretion and CK distribution assessed by immunostaining. Clinicopathological correlations with the clinical features of the patients were established retrospectively.

2. Materials and Methods

2.1. Patients and Clinical Data. Pituitary adenomas surgically removed from acromegaly patients admitted to the Toranomon Hospital (Tokyo, Japan) from 2008 to 2010 were analyzed. The patients’ ages, sex, and hormonal profiles were obtained from clinical records. Basal plasma levels of GH, as well as insulin-like growth factor-1 (IGF-1) and PRL and TSH levels, were measured in the morning after overnight fasting. Maximum tumor diameter, tumor volume, Knosp grade, and sphenoid sinus invasion were evaluated. Sixty-five patients who had been treated before surgery (55 with somatostatin analogues, 8 with dopamine receptor subtype-2 agonist, 2 with both agents) were excluded from analysis of GH and IGF-1 levels, maximum tumor diameter, tumor volume, Knosp grade, and sphenoid sinus.

2.2. Imaging Studies. The maximum tumor diameter was measured by preoperative magnetic resonance imaging (MRI). The tumor volume was estimated on axial, coronal, and sagittal MRI sections as follows: 0.5 × width × length × height [18]. Cavernous sinus invasion by the tumor was classified by MRI according to Knosp et al. [19]. Sphenoid sinus invasion or bony destruction of the sellar floor was judged by a preoperative computed tomography (CT) scan. Patients with a documented history or MRI findings of pituitary apoplexy were excluded from this study.

2.3. Histological Studies. Surgically removed adenoma tissues were fixed in 10% formaldehyde and embedded in paraffin and cut in 3 µm thick sections for hematoxylin-eosin (HE) and immunohistochemical staining. Immunohistochemistry was performed with the avidin-biotin-peroxidase method. Sections were incubated with the following antisera: anti-GH (Dako, Carpinteria, CA, USA; A0570), anti-PRL (Dako, Carpinteria, CA, USA; A0569), anti-beta subunit of TSH (Kyowa Medex Co., Ltd, Tokyo, Japan), anti-Adrenocorticotropic hormone (ACTH) (Dako, Carpinteria, CA, USA; A0571), anti-Follicle stimulating hormone (FSH) (BioGenex, San Ramon, CA, USA; MU026-UC), anti-Luteinizing hormone (LH) (Nichirei Biosciences Inc, Tokyo, Japan), anti-CG (CAM 5.2) (Becton Dickinson, San Jose, CA, USA), and anti-Pit-1 (BD Biosciences, San Jose, CA, USA).

Based on hormone staining, the adenomas were subclassified as GH, GH-PRL, GH-TSH or GH-PRL-TSH adenomas. Each group was further divided into 3 categories according to the pattern of CK staining: tumors with a perinuclear pattern of CK (PP), those with dot-like pattern of CK (DP), and those immunonegative for CK (NP). Adenomas are often composed of a mixture of cells with perinuclear and dot-like patterns; these have clinical features similar to adenomas with the predominantly perinuclear pattern cells, with regard to sex, age, hormone levels, tumor size, and invasiveness [20, 21], and were, therefore, included in the PP category. The latter was further subdivided into a perinuclear predominant group (P-pre), if more than 80% of the cells had perinuclear CK immunoreactivity, and a perinuclear intermediate group (P-inter), when 20% to 80% of the cells had a dot-like CK pattern. Adenomas in which more than 80% of the cells had a dot-like CK pattern were classified DP. The representative staining patterns of P-pre, P-inter, and DP and NP adenomas are shown in Figure 1.

2.4. Statistical Analysis. The data were analyzed by the Chi square test, Mann-Whitney U test, and regression analyses. Differences were considered significant at *P* values <0.05.

3. Results and Discussion

3.1. Patient Profiles. The clinical data of the patients are summarized in Table 1. The age at diagnosis ranged from 18 to 77 years (mean ± SD: 48.0 ± 12.9), and the gender distribution was comparable (107 males and 135 females).

3.2. The Incidence of Monohormonal and Plurihormonal GH Adenomas. There were 108 monohormonal GH adenomas (45%) and 134 plurihormonal adenomas (55%) (Table 2 and Figure 2). The plurihormonal group contained three types of adenomas, GH-PRL (103/134 cases, 77%), GH-TSH (18/134 cases, 13%), and GH-PRL-TSH adenomas (13/134 cases, 10%). Plurihormonality is commonly observed in GH-producing adenomas, around half of which are reported to contain PRL [8]. Yamada et al. reported that 13 out of 31 growth hormone-producing adenomas (42%) were plurihormonal: GH-PRL (7/13 cases, 54%), GH-TSH (3/13 cases, 23%), and GH-PRL-TSH adenomas (3/13 cases, 23%) [13]. More than half of the GH-producing adenomas in our study expressed PRL and/or TSH. All of the examined adenomas were Pit-1-positive, indicating that the acromegaly-causing pituitary adenomas were of the Pit-1 lineage.
3.3. Categorization of the Adenomas by Their CK Patterns. The monohormonal and plurihormonal GH-producing adenomas were further subcategorized according to the distribution of CK immunoreactivity in the cytoplasm. In monohormonal GH adenomas, DG- and SG-type cells can be distinguished, respectively, by their perinuclear or dot-like patterns of CK immunoreactivity in the cytoplasm [10–14, 22–24].

We first examined difference between P-pre and P-inter profiles in the monohormonal and plurihormonal adenomas. There were no significant differences in age, sex, basal GH level, IGF-1 expression, maximum tumor diameter, tumor volume, Knosp grade (>3), and sphenoid sinus invasion, with the exception of IGF-1 levels in GH-PRL adenomas, which were higher in the P-pre than in the P-inter group (749 ± 297 versus 574 ± 203, \(P = 0.015\)). Thus, the P-pre and P-inter types had similar clinical features, justifying their inclusion in the category of PP adenomas.

PP adenomas were the major subtype in all of the monohormonal and plurihormonal GH adenomas: 70% of GH, 89% of GH-PRL, 85% of GH-TSH, and all of GH-PRL-TSH adenomas. DP adenomas were less frequent: 25% of the monohormonal GH adenomas and 5% of GH-PRL adenomas. None of the GH-PRL-TSH and GH-TSH adenomas were classified DP. Only 5% (13/242) of the adenomas were negative for CK.
### Table 2: Clinical, endocrinological, and histological summary of growth hormone producing adenomas.

| Cytokeratin staining | Total cases (n = 242) |
|----------------------|----------------------|
|                      | GH adenoma (n = 108) | GH-PRL adenoma (n = 103) | GH-TSH adenoma (n = 18) | GH-PRL-TSH adenoma (n = 13) |
|                      | PP (n = 78)          | PP (n = 90)              | PP (n = 16)             | PP (n = 13)                  |
|                      | P-pre (n = 46)       | P-pre (n = 26)           | P-pre (n = 7)           | P-pre (n = 5)                |
|                      | P-inter (n = 32)     | P-pre (n = 64)           | P-pre (n = 9)           | P-pre (n = 8)                |
|                      | DP (n = 26)          | P-inter (n = 6)          | P-inter (n = 9)         | DP (n = 0)                   |
|                      | NP (n = 4)           |                     |                     | NP (n = 2)                   |
| Hormonal type        |                      |                     |                     |                     |
| GH adenoma           |                      |                     |                     |                     |
| GH-PRL adenoma       |                      |                     |                     |                     |
| GH-TSH adenoma       |                      |                     |                     |                     |
| GH-PRL-TSH adenoma   |                      |                     |                     |                     |
| Age                  | 49.8 ± 13.0          | 50.1 ± 13.1          | 45.8 ± 12.5          | 45.8 ± 12.0                |
|                      | 41.3 ± 7.80d         | 45.8 ± 12.5          | 34.4 ± 15.2b         | 45.8 ± 12.0                |
|                      | 49.2 ± 12.5          | 44.7 ± 14.6          | 52.2 ± 11.9          | 48.0 ± 12.6                |
| Sex (M/F)            | 7/19c               | 2/4                 | 2/5                 | 8/8                        |
|                      | 42/38               | 15/11               | 25/39               | 3/2                        |
| Cases without preoperative medical therapy (n = 177) |
| Hormonal type        | Total cases (n = 242) |
|                      | GH adenoma (n = 67) | GH-PRL adenoma (n = 87) | GH-TSH adenoma (n = 13) | GH-PRL-TSH adenoma (n = 10) |
|                      | PP (n = 47)         | PP (n = 77)          | PP (n = 11)           | PP (n = 10)                |
|                      | P-pre (n = 21)       | P-pre (n = 21)       | P-pre (n = 6)          | P-pre (n = 3)               |
|                      | P-inter (n = 17)     | P-pre (n = 66)       | P-pre (n = 5)          | P-pre (n = 7)               |
|                      | DP (n = 3)           | P-pre (n = 6)        | P-pre (n = 9)         | DP (n = 0)                  |
|                      | NP (n = 3)           | P-pre (n = 6)        | P-pre (n = 9)         | NP (n = 2)                  |
|                      |                     |                     |                     |                     |
| Age                  | 54.4 ± 11.9          | 50.3 ± 13.3          | 45.5 ± 16.1          | 46.3 ± 13.2                |
|                      | 40.6 ± 7.69          | 51.6 ± 13.5          | 37.1 ± 14.7          | 41.5 ± 10.6                |
|                      | 54.4 ± 10.8          | 50.5 ± 13.2          | 52.0 ± 12.1          | 48.0 ± 13.8                |
| Sex (M/F)            | 14/10               | 45.7 ± 15.4          | 52.0 ± 12.1          | 44.4 ± 13.8                |
|                      | 25/22               | 21/35               | 1/3                 | 1/1                        |
|                      | 5/12                | 2/4                 | 4/2                 | 2/1                        |
|                      | 3/0                 | 5/6                 | 5/6                 | 3/7                        |
|                      |                     |                     |                     |                     |
| GH (basal) (ng/mL)   | 17.6 ± 24.9          | 25.0 ± 21.1          | 17.8 ± 48.8          | 14.6 ± 8.4                 |
|                      | 17.0 ± 14.7          | 23.0 ± 33.2          | 42.8 ± 3.0          | 4.26 ± 3.0                 |
|                      | 19.7 ± 32.0          | 30.5 ± 89.6          | 13.1 ± 17.0          | 12.0 ± 10.9                |
| IGF-1 (U/mL)         | 690 ± 269           | 626 ± 245           | 606 ± 144           | 497 ± 298                 |
|                      | 631 ± 275           | 665 ± 332           | 606 ± 144           | 574 ± 264                 |
|                      | 649 ± 251           | 749 ± 297           | 581 ± 207           | 479 ± 203                 |
|                      | 15.4 ± 11.7          | 14.1 ± 12.9          | 561 ± 299           | 479 ± 203                 |
|                      | 15.4 ± 11.7          | 17.6 ± 8.3          | 581 ± 207           | 479 ± 203                 |
|                      | 7.73 ± 2.10          | 9.44 ± 8.73          | 589 ± 247           | 219 ± 13.5                 |
|                      | 6.9 ± 3.87          | 8.3 ± 4.17          | 589 ± 247           | 83.1 ± 168                |
|                      | 10.1 ± 4.63         | 9.1 ± 2.62          | 29.8 ± 45.1         | 83.1 ± 168                |
|                      | 8.1 ± 5.16          | 11.7 ± 8.60         | 29.8 ± 45.1         | 17.2 ± 13.1                |
|                      | 11.7 ± 8.60         | 83.1 ± 168          | 29.8 ± 45.1         | 23.9 ± 14.2                |
| Table 2: Continued. |
|---------------------|
| **TSH (μIU/mL)**   | 0.80 ± 0.87 | 0.57 ± 0.34 | 0.72 ± 0.16 | 0.90 ± 0.74 | 0.39 ± 0.28 | 0.63 ± 0.44 | 0.85 ± 0.49 | — | 0.78 ± 0.10 | 0.66 ± 0.25 | — | — |
| **Maximum tumor diameter (mm)** | 13.8 ± 6.06 | 21 ± 5.67 | 19 ± 5.19 | 13.8 ± 6.35 | 12.2 ± 2.06 | 17.1 ± 4.26 | 17.9 ± 13.1 | — | 27.5 ± 27.5 | 14.7 ± 7.66 | — | — |
| **Micro (<10 mm)/Macro (>10 mm)** | 17/30 | 0/17 | 0/5 | 33/44 | 1/3 | 6 | 3/8 | — | 1/1 | 4/6 | — | — |
| **Tumor volume (cm³)** | 1.28 ± 2.29 | 3.02 ± 3.43 | 1.69 ± 1.11 | 1.18 ± 3.00 | 0.51 ± 0.41 | 1.76 ± 1.56 | 3.08 ± 5.20 | — | 1.09 ± 1.53 | 1.88 ± 3.60 | — | — |
| **Knosp (3,4)** | 13% | 71% | 0% | 17% | 0% | 33% | 27% | — | 50% | 30% | — | — |
| **Sphenoid sinus invasion** | 17% | 9% | 19% | 16% | 50% | 0% | 33% | 29% | — | — | — | — |

GH: growth hormone; PRL: prolactin; TSH: thyroid stimulating hormone; PP: perinuclear pattern; DP: dot pattern; NP: negative pattern; P-pre: perinuclear predominant pattern; P-inter: perinuclear intermediate pattern; IGF-1: insulin-like growth factor-1; M: male; F: female.

Significantly younger compared with PP GH (P = 0.002), GH-PRL (P = 0.0007), and GH-PRL-TSH (P = 0.01) adenomas. bSignificantly younger compared with PP GH (P = 0.01), GH-PRL (P = 0.01), and GH-PRL-TSH (P = 0.03) adenomas. cSignificantly lower compared with PP GH (P = 0.01), GH-PRL (P = 0.03), and GH-PRL-TSH (P = 0.03) adenomas. dSignificantly lower compared with PP GH (P = 0.01), GH-PRL (P = 0.01), and GH-PRL-TSH (P = 0.03) adenomas. eSignificantly lower compared with PP GH (P = 0.01), GH-PRL (P = 0.01), and GH-PRL-TSH (P = 0.03) adenomas. fSignificantly lower compared with PP GH (P = 0.01), GH-PRL (P = 0.01), and GH-PRL-TSH (P = 0.03) adenomas. gSignificantly larger compared with PP GH (P = 0.0001), GH-PRL (P = 0.0001), and GH-PRL-TSH (P = 0.004) adenomas. hSignificantly larger compared with PP GH (P = 0.0001), GH-PRL (P = 0.0001), and GH-PRL-TSH (P = 0.004) adenomas. iSignificantly larger compared with PP GH (P = 0.0001), GH-PRL (P = 0.0001), and GH-PRL-TSH (P = 0.004) adenomas. jSignificantly larger compared with PP GH (P = 0.0001), GH-PRL (P = 0.0001), and GH-PRL-TSH (P = 0.004) adenomas. kSignificantly larger compared with PP GH (P = 0.0001), GH-PRL (P = 0.0001), and GH-PRL-TSH (P = 0.004) adenomas. lSignificantly larger compared with PP GH (P = 0.0001), GH-PRL (P = 0.0001), and GH-PRL-TSH (P = 0.004) adenomas.
3.4. Clinicopathological Correlations. The results were summarized in Table 2. Monohormonal GH adenomas classed as DP had distinct clinical features. Although basal GH levels and IGF-1 levels did not differ significantly between PP and DP adenomas, the latter occurred frequently in females, at a significantly younger age, they were larger and more advanced according to the Knosp classification, consistent with previous reports [10–13, 22, 25]. One of the characteristic ultrastructural features of sparsely granulated adenomas is formation of fibrous body, which could be identified as a dot-like pattern by CK immunostaining. Thus, the DP GH adenomas represent sparsely granulated somatotroph adenomas known to demonstrate distinct clinical features. In contrast, the clinical features associated with PP and DP types of plurihormonal GH-PRL adenomas were similar. These results indicate that subclassification according to the distribution of CK will help to identify clinically aggressive monohormonal GH adenomas, as previously shown, but not plurihormonal adenomas.

Among the CK-negative (NP) adenomas in our series, there were 4 GH, 7 GH-PRL, and 2 GH-TSH adenomas. The NP GH-PRL adenomas were significantly larger in size and had lower GH levels compared to PP GH-PRL adenomas. NP GH adenomas also tended to become larger than PP GH adenomas. NP GH-TSH adenomas did not differ significantly from PP GH-TSH tumors, but this might be attributed to the small number of such tumors in our series. Yoneda et al. reported a case of a Pit-1 lineage macroadenoma, with weak GH, PRL, and TSH immunoreactivity, and no cytoplasmic CK staining [26]; however, the clinicopathological features of NP GH-producing adenomas have not been well discussed. It will be necessary to accumulate more cases of CK-negative adenomas to determine whether the NP adenoma is a distinct type of pituitary adenoma with potentially aggressive clinical features.

3.5. Serum Hormonal Levels and Tumor Sizes. Unlike prolactinomas, clear correlations have not been established between the size of GH-producing adenomas and serum GH levels [9, 27, 28]. In our study, basal GH levels strongly correlated with tumor volume in PP type monohormonal GH adenomas and GH-PRL adenomas (\( R = 0.777 \) and \( R = 0.931 \), resp.) (Figure 3). In DP- and NP-type adenomas, however, correlation between basal GH levels and tumor volume was not observed. Serum PRL levels also correlated with tumor volume in PP-type GH-PRL-TSH adenomas and tended to correlate with tumor volume in PP GH-PRL adenomas (Figure 4).

4. Conclusions

We examined the clinicopathological features of GH-producing adenomas resected from a large series of 242 acromegaly patients. All of the adenomas were of the Pit-1 lineage and consisted of monohormonal GH adenomas.
(45%) and plurihormonal (GH-PRL, GH-TSH, and GH-PRL-TSH) adenomas (55%). In the group of monohormonal GH adenomas, DP adenomas with CK-positive dot-like structures in a majority of the cells (>80%) were distinguished by the age and sex distribution of the patients, the size of the tumor, and its invasiveness. A small number of adenomas without CK immunoreactivity (5%) also showed a tendency to grow larger in size. Thus, cell typing according to the distribution of CK immunoreactivity will help to distinguish potentially aggressive GH-producing adenomas in acromegaly patients.

**Acknowledgments**

The authors thank Dr. M. Ruberg for a critical reading of the paper, and Ms. K. Ishibashi for her technical support.

**References**

[1] E. Horvath and K. Kovacs, “Pathology of acromegaly,” *Neuroendocrinology*, vol. 83, no. 3–4, pp. 161–165, 2006.

[2] R. Y. Osamura, N. Egashira, H. Kajiya et al., “Pathology, pathogenesis and therapy of growth hormone (GH)-producing pituitary adenomas: technical advances in histochemistry and their contribution,” *Acta Histochemica et Cytochemica*, vol. 42, no. 4, pp. 95–104, 2009.

[3] S. Adler, M. L. Waterman, X. He, and M. G. Rosenfeld, “Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain,” *Cell*, vol. 52, no. 5, pp. 685–695, 1988.

[4] M. Bodner and M. Karin, “A pituitary-specific trans-acting factor can stimulate transcription from the growth hormone promotor in extracts of nonexpressing cells,” *Cell*, vol. 50, no. 2, pp. 267–275, 1987.

[5] T. Minematsu, S. Miyai, H. Kajiya et al., “Recent progress in studies of pituitary tumor pathogenesis,” *Endocrine*, vol. 28, no. 1, pp. 37–41, 2005.

[6] I. Kobayashi, H. Oka, H. Nariyaka, Y. Sato, K. Fuji, and T. Kameya, “Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas,” *Endocrine Pathology*, vol. 13, no. 2, pp. 83–98, 2002.

[7] N. Sanno, A. Teramoto, A. Matsuno, J. Itoh, S. Takekoshi, and R. Y. Osamura, “In situ hybridization analysis of Pit-1 mRNA and hormonal production in human pituitary adenomas,” *Acta Neuropathologica*, vol. 91, no. 3, pp. 263–268, 1996.

[8] M. B. Lopes, “Growth hormone-secreting adenomas: pathology and cell biology,” *Neurosurgical focus*, vol. 29, no. 4, p. E2, 2010.

[9] S. L. Asa, *Tumors of the Pituitary Gland*, Third Series. Atlas of Tumor Pathology, Armed Forces Institute of Pathology, Washington, DC, USA, 1998.

[10] P. R. Mazal, T. Czech, R. Sedivy et al., “Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of acromegalic patients,” *Clinical Neuropathology*, vol. 20, no. 4, pp. 163–171, 2001.

[11] H. Bando, T. Sano, T. Oshima et al., “Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma,” *Endocrinologia Japonica*, vol. 39, no. 4, pp. 355–363, 1992.

[12] T. Sano, T. Ohshima, and S. Yamada, “Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas,” *Pathology Research and Practice*, vol. 187, no. 5, pp. 530–533, 1991.

[13] S. Yamada, T. Aiba, T. Sano et al., “Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology,” *Neurosurgery*, vol. 33, no. 1, pp. 20–27, 1993.

[14] P. E. Neumann, J. E. Goldman, D. S. Horoupian, and M. A. Hess, “Fibrous bodies in growth hormone-secreting adenomas contain cytokeratin filaments,” *Archives of Pathology and Laboratory Medicine*, vol. 109, no. 6, pp. 505–508, 1985.

[15] M. Kasper, P. Stosiek, G. N. P. van Muijen, and R. Moll, “Cell type heterogeneity of intermediate filament expression in epithelia of the human pituitary gland,” *Histochemistry*, vol. 93, no. 1, pp. 93–103, 1989.

[16] E. Horvath and K. Kovacs, “Morphogenesis and significance of fibrous bodies in human pituitary adenomas,” *Virchows Archiv Abteilung B Cell Pathology*, vol. 27, no. 1, pp. 69–78, 1978.

[17] D. M. Toivola, G. Z. Tao, A. Habtezion, J. Liao, and M. B. Omary, “Cellular integrity plus: organelle-related and protein-targeting functions of intermediate filaments,” *Trends in Cell Biology*, vol. 15, no. 11, pp. 608–617, 2005.

[18] P. Lundin and F. Pedersen, “Volume of pituitary macroadenomas: assessment by MRT,” *Journal of Computer Assisted Tomography*, vol. 16, no. 4, pp. 519–528, 1992.
E. Knosp, E. Steiner, K. Kitz et al., "Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings," Neurosurgery, vol. 33, no. 4, pp. 610–618, 1993.

A. Obari, T. Sano, K. Ohyama et al., "Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form," Endocrine Pathology, vol. 19, no. 2, pp. 82–91, 2008.

Y. Bakhtiari, H. Hirano, K. Arita et al., "Relationship between cytokeratin staining patterns and clinicopathological features in somatotropinomas," European Journal of Endocrinology, vol. 163, no. 4, pp. 531–539, 2010.

K. Kovacs, "Pathology of growth hormone excess," Pathology Research and Practice, vol. 183, no. 5, pp. 565–568, 1988.

H. Nishioka, H. Ito, and A. Hirano, "Immunohistochemical demonstration of oncocyes in nongonadotrophic pituitary adenomas," Virchows Archiv, vol. 435, no. 4, pp. 428–433, 1999.

H. Nishioka, J. Haraoka, and K. Akada, "Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas," Clinical Endocrinology, vol. 59, no. 6, pp. 768–772, 2003.

S. Melmed, G. D. Braunstein, E. Horvath, C. Ezrin, and K. Kovacs, "Pathophysiology of acromegaly," Endocrine Reviews, vol. 4, no. 3, pp. 271–290, 1983.

A. Yoneda, T. Sano, S. Yamada et al., "Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity," Endocrine Pathology, vol. 21, no. 1, pp. 40–47, 2010.

H. Nishioka, J. Haraoka, K. Akada, and S. Azuma, "Gender-related differences in prolactin secretion in pituitary prolactinomas," Neuroradiology, vol. 44, no. 5, pp. 407–410, 2002.

H. Nishioka, H. Ito, J. Haraoka, and A. Hirano, "Growth potential of female prolactinomas," Surgical Neurology, vol. 55, no. 4, pp. 213–217, 2001.